Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability (MSAT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Motion style acupuncture treatment(MSAT) is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture. The purpose of this study is to investigate the effect of MSAT in the treating pain and severe functional disability in acute LBP patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Complete Immobility Due to Severe Physical Disability |
Other: acupuncture, injection |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability: a Randomised, Controlled, Trial Protocol |
- Change from Baseline in numerical rating scale of back pain [ Time Frame: Before treatment, At 30 minutes, 2, 4, and 24 weeks after treatment. ] [ Designated as safety issue: No ]
- Change from Baseline in NRS of radiating pain, ODI scores, and the patient's global impression of change(PGIC),range of motion (ROM) of the lumbar spine, and degrees of straight leg raising (SLR) [ Time Frame: Before treatment, At 30 minutes, 2, 4, and 24 weeks after treatment. ] [ Designated as safety issue: Yes ]Post-treatment follow-up will be performed to measure primary and secondary outcomes with the exception of ROM and SLR at 2, 4, and 24 weeks after treatment.
| Enrollment: | 58 |
| Study Start Date: | April 2011 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: acupuncture
MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
|
Other: acupuncture, injection
MSAT and intramuscular injections of diclofenac(NSAID)
|
|
Active Comparator: injections of diclofenac
the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
|
Other: acupuncture, injection
MSAT and intramuscular injections of diclofenac(NSAID)
|
Detailed Description:
58 patients with acute LBP and severe disability with an Oswestry Disability Index(ODI) of 60% or higher were randomly allocated and divided into 2 groups. The experimental group was treated with MSAT and the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session, and comparisons were made of measurements before and after treatment. Primary outcomes were measured by the NRS(numerical rating scale) of back pain in active movement. Secondary outcomes were measured by the NRS of radiating pain, ODI scores, and the patient's global impression of change(PGIC) etc. Post-treatment follow-up will be performed to measure primary and secondary outcomes with the exception of ROM and SLR at 2, 4, and 24 weeks after treatment.
Eligibility| Ages Eligible for Study: | 20 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute LBP(with or without leg pain), with onset within past 4 weeks
- Severe disability as assessed by an Oswestry Disability Index of 60% or higher
- Age between 20 and 60
- Given consent to lumbar MRI
- Voluntary participation with written consent given to study consent form
Exclusion Criteria:
- Diagnosis of serious disease(s) which are possible causes of back pain such as malignancy, vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc.
- Prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, Alzheimer's disease, epilepsy, etc.
- Progressive neurologic deficit(s) or concurrent severe neurological symptoms
- Unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc.
- Under prescription of corticosteroids, immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher
- Experience of gastroenteric complications after taking NSAIDs or currently undergoing treatment for digestive disorders
- During pregnancy or suspected pregnancy
- Subjects considered unsuitable for clinical trial by the researcher
Contacts and Locations| Korea, Republic of | |
| Jaseng Oriental Hospital | |
| Seoul, Gangnamgu Sinsadong, Korea, Republic of | |
| Jaseng Oriental Hospital | |
| Bucheon, Korea, Republic of | |
| Principal Investigator: | Joonshik Shin | JASENG HOSPITAL |
More Information
No publications provided by Jaseng Hospital of Oriental Medicine
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jaseng Hospital of Oriental Medicine |
| ClinicalTrials.gov Identifier: | NCT01315561 History of Changes |
| Other Study ID Numbers: | JSR-2011-01 |
| Study First Received: | March 14, 2011 |
| Last Updated: | October 3, 2012 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Jaseng Hospital of Oriental Medicine:
|
acute low back pain motion stlye acupuncture treatment disability MSAT |
Additional relevant MeSH terms:
|
Back Pain Low Back Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Diclofenac Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013